Evidence map›Paper›PMID 38495810›Full record

ArticleCardiovascular therapeutics2024

DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways.

Lu Chen, Hongyu Su, Zekai Tao, Cui Liang, Zhongzhao Liu, Yiming Dong, Peipei Zheng, Yuan Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lu ChenDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID https://orcid.org/0009-0004-2685-7392
Hongyu SuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zekai TaoDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Cui LiangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhongzhao LiuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yiming DongDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Peipei ZhengDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuan LiuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID https://orcid.org/0000-0003-3521-6410
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial-to-mesenchymal transition (EndMT) is the process by which endothelial cells lose their endothelial properties and acquire mesenchymal characteristics. Dual-specific protein phosphatase 22 (DUSP22) inactivates various protein kinases and transcription factors by dephosphorylating serine/threonine residues: hence, it plays a key role in many diseases. The aim of this study was to explore the functional role of DUSP22 in EndMT. In the transforming growth factor-

Indexed as

MAP Kinase Signaling SystemPhosphoprotein PhosphatasesDown-RegulationDual-Specificity PhosphatasesEndothelial-Mesenchymal TransitionHumansHuman Umbilical Vein Endothelial CellsMitogen-Activated Protein Kinase PhosphatasesSmad2 ProteinSmad3 ProteinDual-Specificity PhosphatasesDUSP22 protein, humanMitogen-Activated Protein Kinase PhosphatasesPhosphoprotein PhosphatasesSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, human

Identifiers

PMID38495810
PMCPMC10942825
OpenAlexW4392620548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.